跳至主要内容
临床试验/JPRN-jRCT2080224825
JPRN-jRCT2080224825已完成2 期

Continuous administration trial of phase II study of bexarotene in patients with adult T-cell leukemia/lymphoma (ATL)

Minophagen Pharmaceutical Co., Ltd.0 个研究点目标入组 10 人开始时间: 2019年8月7日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1. Patients who participated in and completed the B-1801 trial.
  • 2. Patients who can agree to use effective contraception method.
  • Fertile female subject:
  • During study drug administration and 1 month after completion of study drug administration.
  • Male subjects with pregnant women as partners:
  • During study drug administration and 3 months after completion of study drug administration.
  • 3. Patient who agreed in writing about participation in this trial by last visit of the B-1801 trial.

排除标准

  • 1. Patients who evaluated the efficacy at PD by mSWAT or the modified response criteria for ATL at last visit of the B-1801 trial.
  • 2. On other, patients judged not to be appropriate for participation in the trial by investigators.

研究者

相似试验